DLL3 expression
DLL3 sits on the surface of about 85 percent of small-cell lung cancers and almost no normal adult tissue. Tarlatamab is given without a DLL3 test.
Overview
Tarlatamab (Imdelltra) is a DLL3 x CD3 bispecific labelled for extensive-stage small-cell lung cancer after platinum chemotherapy; the DeLLphi trials enrolled without DLL3 selection and the label names DLL3 only as the target. DLL3-directed ADCs, radioligands and CAR-T cells in trials likewise do not gate on expression, and a DLL3 PET tracer is under study.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · A protein that appears on the surface of small-cell lung cancer cells, now hit by a drug that pulls T cells onto them.
Tarlatamab does not require a DLL3 test; the target is present in most small-cell lung cancers. Treatment starts in hospital because of the risk of cytokine release in the first cycle.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager”
IMDELLTRA prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
- NCT06211036 · 2026DeLLphi-305
- NCT05740566 · 2025DeLLphi-304
- NCT04471727A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- NCT07174583A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- NCT05652686A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT07218146A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- NCT07564401A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
- NCT07744256Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
- NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
- NCT07544654DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- NCT05882058DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- NCT03061812Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
- NCT07278479Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Similar pages
not linked directly; found by shared links- BiomarkerBCMA expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCD38 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCEACAM5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerFcRH5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerGPRC5D expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerHER3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerNectin-4 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerTissue factor expression
Shares the tags biomarker, surface-antigen, no-threshold.